

MICROBIOLOGY OF NONSTERILE PHARMACEUTICAL MANUFACTURING

RANGA VELAGALETI

BASF Corporation, Florham Park

Contents

- 1 Introduction
- 2 Global Regulations and Regulatory Guidances Relevant to Microbial Bioburden Control during Nonsterile Manufacturing
 - 2.1 GMPs for Finished Products and Components of Finished Products
 - 2.2 GMPs for Active Pharmaceutical Ingredients
 - 2.3 GMPs for Bulk Pharmaceutical Excipients
- 3 Pharmacopeial Guidelines Relevant to Microbiology of Nonsterile Manufacturing
 - 3.1 United States Pharmacopeia
 - 3.2 European Pharmacopoeia
 - 3.3 Japanese Pharmacopoeia
- 4 Current Regulatory Expectations for Microbial Bioburden Control during Nonsterile Manufacturing
- 5 Industry Perspective on Microbial Bioburden Control for Nonsterile Pharmaceutical Manufacturing
 - 5.1 Survey Results
 - 5.2 Recommendations
- 6 Microbial Bioburden Control during Shelf Life of Pharmaceutical Products
- 7 Summary and Conclusions
- References

1 INTRODUCTION

In order to comply with general microbiological quality attributes for nonsterile pharmaceuticals and established monograph or drug application specifications for

Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing

Edited by Shayne C. Gad

Copyright © 2010 John Wiley & Sons, Inc.